Overactive bladder symptoms recurrence after sudden versus gradual weaning of Solifenacin

Solifenacin significantly improves all symptoms of overactive bladder syndrome

Overactive bladder syndrome (OAB) is a chronic condition characterised by urgency, with or without associated urge incontinence. Solifenacin succinate is a once daily, bladder selective antimuscarinic available in two doses (5 and 10 mg). The recommended dose is 5 mg once daily and can be increased to 10 mg once daily if 5 mg is well tolerated. This article presents pooled efficacy and safety d...

Solifenacin succinate (VESIcare): overactive bladder therapy.

Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study

PURPOSE To compare the clinical efficacy of anticholinergics for managing diabetes mellitus-associated overactive bladder (DM OAB) versus idiopathic overactive bladder (OAB) in Korean women. METHODS We conducted a multicenter, prospective, parallel-group, open-label, 12-week study. Women (20-65 years old) with OAB symptoms for over 3 months were assigned to the DM OAB and idiopathic OAB group...

Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.

BACKGROUND The efficacy of antimuscarinic drug therapy in patients who have more severe symptoms of overactive bladder (OAB) at baseline has not been evaluated thoroughly. OBJECTIVE This analysis determined the effects of solifenacin in patients with severe OAB symptoms at baseline. METHODS All randomized, placebo-controlled phase III studies of solifenacin were pooled to determine the effe...

Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment

PURPOSE To identify incidence and risk factors of recurrence after discontinuation of successful antimuscarinic therapy in patients with overactive bladder (OAB). MATERIALS AND METHODS This was a prospective, multicenter trial. Patients who had antimuscarinic agents for more than 12 weeks and showed successful response were enrolled. Successful response was defined as answering 'benefit' for ...